-

OWLT Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Owlet, Inc. (NYSE: OWLT) Investors

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Owlet, Inc. (NYSE: OWLT) (“Owlet”).

Owlet operates as a digital parenting platform in the United States. Owlet’s platform focuses on giving real-time data and insights to parents. Its products include: Owlet Monitor Duo that gets the snapshot of the baby’s wellbeing; Owlet Smart Sock that tracks the baby’s heart rate and oxygen while sleeping and get notifications if the baby needs to be checked on; Owlet Cam, a smart HD video baby monitor; and Dream Lab, an online and personalized infant sleep solution.

On October 4, 2021, Owlet disclosed that it received a Warning Letter from the U.S. Food and Drug Administration (“FDA”). The FDA’s letter informed Owlet that its marketing for its Owlet Smart Sock in the United States “renders the Smart Sock a medical device requiring premarket clearance or approval from FDA, and that [Owlet] has not obtained such clearance or approval in violation of the Federal, Food, Drug, and Cosmetic Act.” The FDA has requested that Owlet take “prompt action” to remedy the alleged violations.

Following this news, Owlet’s shares fell sharply during intraday trading on October 4, 2021, down over 22%.

If you are an Owlet investor, please CLICK HERE to learn more about our investigation. You may also contact attorney James Maro, Esq. (484) 270-1453 or Toll Free at (844) 887-9500 or via e-mail at info@ktmc.com.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.

Contacts

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
280 King of Prussia Road
Radnor, PA 19087
(844) 887-9500
info@ktmc.com

Kessler Topaz Meltzer & Check, LLP

NYSE:OWLT

Release Summary
Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Owlet, Inc. (NYSE: OWLT) Investors
Release Versions
$Cashtags

Contacts

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
280 King of Prussia Road
Radnor, PA 19087
(844) 887-9500
info@ktmc.com

More News From Kessler Topaz Meltzer & Check, LLP

uniQure N.V. (QURE) Investors: Kessler Topaz Meltzer & Check, LLP Announces That the Firm Has Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. and Encourages Investors to Contact the Firm

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against uniQure N.V. (NASDAQ: QURE) (“uniQure” or the “Company”) on behalf of investors who purchased or acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025, inclusive (the “Class Period”). This action, captioned Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124, was filed in the United States District Court for...

RARE Investors: Kessler Topaz Meltzer & Check, LLP Reminds Investors of April 6, 2026 Deadline in Securities Fraud Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical Inc.

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (Ultragenyx) (NASDAQ: RARE) on behalf of those who purchased or acquired Ultragenyx common stock between August 3, 2023, and December 26, 2025, inclusive. The lawsuit is filed in the United States District Court for the Northern District of California and is captioned Bailey v. Ultragenyx Pharmace...

NYSE: RAL Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Ralliant Corporation (NYSE: RAL) Investors to Contact the Firm

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Ralliant Corporation (NYSE: RAL). On February 4, 2026, Ralliant Corporation reported its fourth quarter and full year 2025 financial results and revealed a $1.4 billion non-cash goodwill impairment charge recorded in the Test & Measurement segment, which the company stated was mainly driven by revised exp...
Back to Newsroom